Sarepta Therapeutics (SRPT)

May 13, 2025, 9:25 AM EDT - 17 hours ago

Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy

May 9, 2025, 7:16 AM EDT - 4 days ago

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

PRTA RXST

May 8, 2025, 4:30 PM EDT - 5 days ago

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference

May 7, 2025, 2:14 PM EDT - 6 days ago

Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating

May 7, 2025, 1:07 PM EDT - 6 days ago

Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up

May 7, 2025, 12:14 PM EDT - 6 days ago

Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade

May 7, 2025, 11:13 AM EDT - 6 days ago

New vaccine chief rocks pharmaceutical stocks

BNTX MRNA NVAX PFE GSK IBB XBI

May 7, 2025, 9:28 AM EDT - 6 days ago

Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results

May 7, 2025, 8:10 AM EDT - 6 days ago

Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

ANET MRCY

May 6, 2025, 10:41 PM EDT - 7 days ago

Sarepta Therapeutics, Inc. (SRPT) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 7 days ago

Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

May 5, 2025, 9:00 AM EDT - 8 days ago

SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Apr 22, 2025, 8:30 AM EDT - 21 days ago

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

Apr 15, 2025, 8:30 AM EDT - 4 weeks ago

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs

Apr 4, 2025, 8:55 AM EDT - 5 weeks ago

Sarepta halts three studies testing gene therapy for muscle disorder

Apr 4, 2025, 8:44 AM EDT - 5 weeks ago

Sarepta Therapeutics Provides Update on ELEVIDYS

Apr 3, 2025, 3:23 PM EDT - 5 weeks ago

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

Apr 3, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Shareholders to Connect

Apr 2, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Shareholders to Reach Out

Apr 1, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Shareholders to Learn More About the Investigation

Mar 31, 2025, 5:54 PM EDT - 6 weeks ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 2:25 PM EDT - 6 weeks ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX NVAX SLDB TSHA XBI

Mar 31, 2025, 10:00 AM EDT - 6 weeks ago

Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Mar 30, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation

Mar 28, 2025, 10:00 AM EDT - 6 weeks ago

Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Mar 27, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Investors to Connect

Mar 26, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation

Mar 24, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect

Mar 23, 2025, 10:00 AM EDT - 7 weeks ago

Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Mar 21, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Stockholders to Learn More About the Investigation

Mar 20, 2025, 1:55 PM EDT - 7 weeks ago

Sarepta: Should Investors Run For The Exit?

Mar 20, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation

Mar 19, 2025, 4:00 PM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Investors to Reach Out

Mar 18, 2025, 6:16 PM EDT - 2 months ago

Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Mar 18, 2025, 1:30 PM EDT - 2 months ago

S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge

IVV SPLG SPXL SPY SSO UPRO VOO

Mar 18, 2025, 9:54 AM EDT - 2 months ago

Sarepta Therapeutics' stock falls after patient dies of liver failure

Mar 18, 2025, 9:29 AM EDT - 2 months ago

Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges

Mar 18, 2025, 8:17 AM EDT - 2 months ago

Sarepta says patient dies after treatment with gene therapy

Mar 4, 2025, 8:15 AM EST - 2 months ago

Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness

Feb 28, 2025, 9:00 AM EST - 2 months ago

Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program

Feb 26, 2025, 11:48 PM EST - 2 months ago

Sarepta Therapeutics, Inc. (SRPT) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 2 months ago

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments

Feb 18, 2025, 10:20 AM EST - 3 months ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE KRYS MARA

Feb 14, 2025, 8:30 AM EST - 3 months ago

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility

Feb 12, 2025, 8:30 AM EST - 3 months ago

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results

Feb 10, 2025, 8:30 AM EST - 3 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

ARWR